Engflag

Sonic - P

Quick links to important sections

Sonic - P

Sonic - P_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sonic - P

Quick Facts

Property Description
Active Ingredients Aceclofenac, Paracetamol (Acetaminophen)
Form Oral Tablet
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Analgesic/Antipyretic
General Purpose Simultaneous relief of pain, inflammation, and fever
Origin Synthetic medicine

What Type of Medicine is Sonic-P? (Classification and Origin)

Sonic-P is a synthetic medicine provided as a fixed-dose combination product, typically in an oral dosage form such as a tablet. It is classified within the pharmacological class of both a Nonsteroidal Anti-inflammatory Drug (NSAID) and an Analgesic/Antipyretic. This dual classification stems from its two active ingredients: Aceclofenac and Paracetamol (Acetaminophen). The use of Paracetamol as a foundational agent for pain and fever is a standard application for this ingredient.

Composition: What are Aceclofenac and Paracetamol? (Active Ingredients)

This medicine’s identity rests on the complementary roles of Aceclofenac and Paracetamol, both of synthetic origin. Aceclofenac provides the anti-inflammatory action by modulating chemical messengers involved in swelling, while Paracetamol acts centrally to increase the body's pain threshold and reduce fever. The Aceclofenac-Paracetamol combination is intended for pain relief in acute painful conditions to allow for a synergistic benefit. Combining the components is designed to provide faster and more complete relief of acute discomfort compared to using only the anti-inflammatory component. This combined action is prepared into a stable oral dosage form using pharmaceutical excipients.

General Purpose: What Does the Sonic-P Combination Achieve? (Benefit)

The general purpose of the Sonic-P combination is to provide symptomatic management by addressing three major factors: pain, inflammation, and fever. This strategy of using a fixed-dose combination leverages different mechanisms to manage acute symptoms. This approach aligns with the concept that combining drugs with different mechanisms is a method for managing acute pain. This comprehensive approach leverages both components to deliver integrated relief, a feature that distinguishes it from monotherapy alternatives.

Regulatory References

  1. Paracetamol on the WHO Essential Medicines List

What side effects are possible with Sonic - P?

Possible Side Effects and Safety Information

The safety profile for Sonic-P, a fixed-dose combination containing an NSAID (Aceclofenac) and Paracetamol, is defined by regulatory agencies based on categorized adverse reactions and documented safety constraints.

Official Adverse Reaction Scope

Adverse reactions are classified primarily by the organ systems affected (System-Organ Classes) and their reported frequency. The most common adverse effects documented in official labeling are typically gastrointestinal disorders, including dyspepsia, nausea, abdominal pain, and diarrhoea.

Frequencies are officially categorized, where rare events include anaphylactic reactions and hypersensitivity, and very rare events include certain serious skin reactions.

Serious Adverse Reactions and Safety Constraints

Regulatory documents explicitly list potential serious adverse reactions. These include severe gastrointestinal events, such as bleeding, ulceration, or perforation, which are acknowledged risks associated with the NSAID component. The profile also highlights the potential for serious skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis) and the risk of cardiovascular thrombotic events (myocardial infarction and stroke).

Safety constraints and contraindications limit use in specific populations. The medicine is contraindicated in individuals with active or a history of recurrent peptic ulcers or hemorrhage, and in those with severe hepatic impairment. Due to the NSAID component, caution is required for older adults, who are at a heightened risk for serious GI and renal adverse events, and those with established cardiovascular conditions.

Time-related safety patterns are also noted; the risk of certain serious skin reactions is documented as being highest early in the course of therapy. This information structures the understanding of the medicine’s risk profile by detailing the spectrum of reported effects and the specific conditions that limit its use.

Overdose and Emergency Response

The official regulatory profile for a Sonic-P overdose is defined by the combined risks of its two active components. Initial manifestations documented in regulatory sources may include nausea, vomiting, dizziness, epigastric pain, or drowsiness. The most severe, life-threatening consequence is Acute Liver Failure (hepatic necrosis) stemming from the Paracetamol component, with critical signs like jaundice or confusion potentially appearing as a delayed symptom 24 to 48 hours following ingestion. The Aceclofenac component adds documented risks of Acute Renal Failure, severe Gastrointestinal Bleeding, and central nervous system effects such as Convulsions.

Seeking Immediate Medical Help:

Regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose, even if the individual appears to be asymptomatic. This action is critical because the specific antidote for the Paracetamol component, N-acetylcysteine (NAC), is most effective when administered quickly, guided by plasma drug concentration. Treatment is symptomatic and supportive, requiring close and continuous hospital monitoring of both liver and renal function. Regulatory information notes that elderly patients face an increased risk of severe, potentially fatal gastrointestinal complications in overdose scenarios.

Therapeutic Uses of Sonic - P

The primary therapeutic roles of this class of medicine are to temporarily relieve pain and temporarily reduce fever. Sonic-P is primarily applied in scenarios where additional management of discomfort is required, such as for headaches, general body aches, muscular discomfort, and mild swelling associated with inflammatory states. It is commonly used across conditions presenting with acute episodes like the common cold or flu, or in situations related to minor injuries, where symptoms create noticeable physiological strain. The medication is intended to address symptom clusters that may become intense or disruptive, offering a supportive approach.

“The intent is to provide symptomatic relief that supports patients during difficult episodes.”

By moderating elevated temperature and easing physical discomfort, Sonic-P contributes to comfort during periods of heightened symptoms and assists with maintaining a sense of stability when symptoms interfere with routine activities. It is relevant when supportive symptom management is appropriate.

Quick Fact: Relief for Body Aches and Fever

Eligibility and Restrictions for Use

Who Can and Cannot Use Sonic-P?

Eligibility for this fixed-dose combination is governed by official regulatory documentation, which outlines absolute contraindications and populations requiring restricted use.

Populations Contraindicated (Must Not Use):

  • Hypersensitivity: Known allergy to Aceclofenac, Paracetamol, aspirin, or other NSAIDs that cause reactions like asthma or urticaria.
  • Organ Failure: Patients with severe heart, hepatic, or renal failure.
  • Gastrointestinal: Active or recurrent peptic ulceration, GI bleeding, or perforation.
  • Cardiovascular: Established congestive heart failure (NYHA II–IV), ischemic heart disease, or cerebrovascular disease.
  • Pregnancy: Use is contraindicated in the third trimester of pregnancy.

Restricted and Not Recommended Populations:

  • Age: The medicine is not recommended for children due to insufficient clinical data. The elderly require close surveillance due to increased risk of complications.
  • Organ Function: Patients with mild-to-moderate hepatic or renal impairment must use the medicine only with caution and surveillance.
  • Reproductive: Use is not recommended for women who are breastfeeding or attempting to conceive.

This structure defines the official eligibility, limiting use to adults who do not possess these documented risk factors or conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns for Sonic-P (Aceclofenac and Paracetamol/Acetaminophen), based strictly on regulatory prescribing information.

Contraindicated Combinations and Restrictions:

Co-administration with other NSAIDs or Paracetamol-containing products is strictly prohibited due to the severe risk of overdose or serious gastrointestinal adverse events, including ulceration. The NSAID component is formally restricted for pain management following Coronary Artery Bypass Graft (CABG) surgery. Consumption of three or more alcoholic drinks per day while using this medicine is officially associated with an increased risk of severe liver damage.

Clinically Significant Drug Interactions:

Interacting Class/Medicine Official Interaction Statement
Antihypertensives / Diuretics NSAID component may diminish the therapeutic effect of these agents.
Warfarin / Coumarins Risk of increased bleeding due to potentiation of the anticoagulant effect.
Lithium, Digoxin, Methotrexate NSAID component may increase the plasma concentrations and toxicity of these medicines by reducing their clearance.
Hepatic Enzyme Inducers Increases the potential for Paracetamol hepatotoxicity via metabolic pathways.

Timing-Based Constraints:

Administration requires separation from certain substances. For example, NSAIDs should not be used for 8–12 days following administration of Mifepristone, and Cholestyramine must not be given within one hour of the medicine to prevent reduced absorption. These constraints are formalized in regulatory labeling.

Mechanism of Action

How Sonic - P Works: Pharmacodynamic Mechanism

Sonic-P exerts its action through two distinct, complementary pharmacodynamic mechanisms. The Aceclofenac component functions as an inhibitor of Cyclooxygenase (COX) enzymes, predominantly the COX-2 isoform, in peripheral tissues. This molecular interaction suppresses the biosynthesis of pro-inflammatory mediators, primarily prostaglandins, thereby modifying the eicosanoid cascade. The subsequent restricted sensitization of local nociceptors and the attenuation of localized tissue responses constitute the peripheral physiological effect.

The Paracetamol component acts primarily within the Central Nervous System (CNS). It contributes to an elevation of the pain processing threshold through modulation of descending inhibitory pathways and acts on COX enzymes within the hypothalamus. This central activity modulates two system-level functions: the central processing of nociception and the lowering of the body's elevated temperature set point. The combined effect is a non-overlapping dual-site action, intervening in both peripheral signaling and central regulatory pathways.

Dosage and Administration Information

How Sonic - P is Used

Sonic-P is a fixed-dose combination product containing Aceclofenac and Paracetamol, which is administered via the oral route as a tablet.

Standard Dosing and Administration

The standard adult dosing regimen is typically one tablet taken twice daily, separated by an approximate 12-hour interval. This schedule establishes a maximum daily limit of two tablets. The medication is typically swallowed whole with a sufficient amount of liquid and is taken with or immediately after food to help mitigate potential gastrointestinal discomfort.

The general principle for this class of medication is to use the lowest effective dose for the shortest duration necessary to manage symptoms. Instructions generally specify not to combine this product with any other medicine containing paracetamol to prevent exceeding the total daily Paracetamol safety limit from all sources.

Population-Specific Use

Dose adjustment is specified for certain patient groups. For individuals with hepatic impairment, a reduced initial daily dose is often used, with some specifications indicating one tablet daily. Conversely, for both elderly patients and those with mild renal impairment, routine dose modification is generally not required, although general clinical caution is applied in line with standard NSAID usage principles.

Recent Clinical Evidence

Research has focused on the study of the fixed-dose combination of Aceclofenac and Paracetamol for conditions associated with acute or disruptive episodes, such as pain and inflammation related to musculoskeletal disorders. These symptomatic states are conditions where symptoms may vary in intensity and are often marked by functional limitations. The structure of the evidence includes Randomized Controlled Trials (RCTs) and systematic reviews.

These studies explored how symptoms changed over short periods, with researchers measuring patient-reported experiences of physical discomfort using validated scales. Studies were often designed to observe comparative patterns when the combination was evaluated against its individual components (monotherapies) and against placebo. Research describes patterns related to symptom intensity or variability that were observed when comparing the different treatment approaches used in the clinical trials.

The evidence base is structured around the short-term study of symptoms in specific adult populations. The majority of research exploring this combination has focused on short-term symptom changes, and follow-up durations were limited, often spanning only a few days or weeks. Consequently, long-term outcomes are not fully established, and there is limited information available for continuous, extended periods of use.

Clinical research mainly focused on adult populations with musculoskeletal disorders. For key demographics like children, older adults, or pregnant populations, data remain insufficient. This means that the results apply only to the populations studied. Key research limitations include the limited follow-up durations and the concentration of available clinical evidence within specific international settings. Research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. WHO Model List of Essential Medicines – 23rd List, 2023

Frequently Asked Questions (FAQ)

Common questions about Sonic - P (FAQ)

Q: What happens if I stop taking Sonic - P suddenly?

Official regulatory documents advise consulting a healthcare professional before stopping treatment. This guidance supports appropriate discontinuation and monitoring through a healthcare professional.

Q: Can I drive or use heavy machinery while taking Sonic - P?

The official product information notes that the medicine may cause effects such as dizziness, somnolence (drowsiness or sleepiness), or visual disturbances. If these effects occur, the product label advises against driving or operating machinery. Understanding the medicine’s effect on the body is generally considered before engaging in activities that require full mental alertness.

Q: Is Sonic - P known to cause weight gain or weight loss?

According to official regulatory documents, weight increase is listed as a very rare undesirable effect. This effect is described in relation to fluid retention or oedema (swelling), which is a possibility with the anti-inflammatory component of the medicine.

Q: How quickly does Sonic - P start working, and how long does it last?

Regulatory documents containing pharmacokinetic information describe the time frames for the components in the body. The Aceclofenac component typically reaches its highest level in the blood approximately 1.25 to 3.00 hours after the dose is taken. Its effect starts to decline after this peak, with an elimination half-life of around 4 hours.

Q: Does Sonic - P contain any controlled substances or have a risk of dependence?

Official product labeling and scheduling information indicate that the active ingredients in Sonic - P, Aceclofenac and Paracetamol, are not classified as controlled substances. Therefore, the medicine does not possess the dependence profile associated with scheduled narcotic medicines.

Q: Can Sonic - P interact with herbal supplements like St. John's Wort or Ginkgo?

Interactions between the components of Sonic - P and various herbal products are possible. For example, regulatory information notes that combining the Aceclofenac component with Ginger may enhance the effects of anticoagulation. Official guidance often recommends informing a healthcare professional about all supplements being taken.

Q: Can Sonic - P cause sleepiness or affect my alertness?

Yes, official reports list dizziness and somnolence (a medical term for drowsiness or sleepiness) as reported undesirable effects. Monitoring one’s body's response, particularly when starting a medication, is generally advised.

Q: What if I accidentally miss a dose of Sonic - P?

Official patient information states that if a dose is missed, the next scheduled dose should be taken at the usual time. Regulatory advice states that a double dose should not be taken to make up for a forgotten dose.

Q: What are the official documents or labels for Sonic - P called?

The formal regulatory documents describing the medicine are known by different names depending on the region. In Europe, they are commonly called the Summary of Product Characteristics (SmPC). In the US, the documents are referred to as the Prescribing Information or the FDA Label.

Q: Do I need any special tests (e.g., blood work) before or during treatment with Sonic - P?

According to the official product information, regular monitoring is recommended for individuals receiving long-term treatment. This monitoring typically involves checks of renal function tests (kidney), liver function tests, and blood counts to support appropriate safety surveillance.

Q: Can I take Sonic - P if I have a history of seizures?

Regulatory information indicates that the Aceclofenac component may potentially precipitate convulsions when used alongside certain medicines, specifically quinolone antibiotics. Information regarding a history of seizures and potential risk factors is generally reviewed by a healthcare professional.

Q: What are the major drug interactions for Sonic - P, such as with antidepressants?

Official documents list multiple significant drug interactions. For example, combining the Aceclofenac component with selective serotonin reuptake inhibitor (SSRI) antidepressants is described as increasing the risk of gastrointestinal bleeding.

Q: Is there a link to official regulatory documents about Sonic - P?

Official regulatory documents are published by the relevant national government authorities that authorize the medicine. These include agencies such as the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), or Health Canada.

How should Sonic - P be stored and disposed of?

The storage and disposal of Sonic-P (Aceclofenac/Paracetamol tablets) must strictly follow the requirements documented in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Condition Regulatory Mandate
Temperature Store below 30 C (room temperature). Do not freeze.
Protection The medicine must be protected from light and moisture.
Container Keep the tablets in the original package and ensure the container is tightly closed.
Child Safety Keep this medicine out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Sonic-P must not be disposed of via household trash or wastewater. Disposal must adhere to local requirements for pharmaceutical waste management, typically involving drug take-back programs or designated collection points, to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sonic - P found in:

A-Z Index: